 |
11 Diseases |  |
24 Trials |
|
24 Trials |  |
1081 News |  |
| «12345678910111213...1314» |
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Short-term Tezepelumab effectiveness in patients with severe asthma: a multicentre study. (Pubmed Central) - Sep 26, 2024
Tezepelumab demonstrated short-term efficacy in improving asthma control and quality of life, showing a favourable safety profile. Further studies with larger sample sizes and longer follow-up would confirm these findings and identify predictors of response to Tezepelumab.
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Clinical, Journal: Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study. (Pubmed Central) - Sep 24, 2024
In real-world scenarios, despite the study's limitations, our results underscore Tezepelumab's promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.
- |||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion date, Trial primary completion date, HEOR, Real-world evidence, Real-world: ASCENT: A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (clinicaltrials.gov) - Sep 19, 2024
P=N/A, N=550, Recruiting, Sponsor: AstraZeneca
Further studies are needed to corroborate these findings. Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026
- | QX008N / Qyuns Therap
Journal, Combination therapy: Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody. (Pubmed Central) - Sep 15, 2024
Trial completion date: Nov 2025 --> Mar 2026 | Trial primary completion date: Nov 2025 --> Mar 2026 These results furnish comprehensive preclinical evidence for QX008N as an innovative anti-TSLP therapeutic agent and provide a preliminary rationale for the development of combination therapies that simultaneously target the TSLP and IL-4R signaling pathways.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
EFFICACY OF TEZEPELUMAB IN ADULTS WITH MODERATE TO VERY SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOOD EOSINOPHIL COUNT AND SMOKING HISTORY: PHASE 2A COURSE STUDY (Convention Center Exhibit Hall: Rapid Fire Area 3A) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6713;
P2
CLINICAL IMPLICATIONS: This analysis supports the efficacy of tezepelumab in patients with COPD and BECs of ? 150 cells/?L who are current or former smokers.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal, Real-world evidence, Real-world: Real-world data on tezepelumab in patients with severe asthma in Germany. (Pubmed Central) - Sep 8, 2024
In this real-life cohort, including a large proportion of patients with history of previous biologic use and encompassing various subgroups, the majority responded to tezepelumab. Our data further suggest a steroid-sparing effect of tezepelumab.
- Asthma biologic therapy and time to next cystic fibrosis pulmonary exacerbation () - Sep 4, 2024 - Abstract #NACFC2024NACFC_1334;
These preliminary results indicate a potential role for asthma biologics in PwCF and may improve control of CF infections in reduction of PEx. Further work on patient selection for these asthma therapies is warranted.
- Difficult asthma: Pearls and pitfalls (Hall 303, Level 3) - Aug 27, 2024 - Abstract #MTS2024MTS_27;
Tezepelumab also treats non-Type 2 asthma but is only licensed for children aged 12 years and over...This should include determining what went wrong, and if necessary, developing a new asthma plan. An asthma attack is an acute sign of suboptimal management of a chronic disease
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Xolair (omalizumab) / Roche, Novartis
Review, Journal: Exploring the therapeutic potential of monoclonal antibodies targeting TSLP and IgE in asthma management. (Pubmed Central) - Aug 27, 2024
An asthma attack is an acute sign of suboptimal management of a chronic disease The overarching objective of this comprehensive study is to delve into the latest advancements in asthma therapeutics and to provide guidance for future investigations in this domain.
- ||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion: DIRECTION: Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma (clinicaltrials.gov) - Aug 25, 2024
P3, N=405, Completed, Sponsor: AstraZeneca
The overarching objective of this comprehensive study is to delve into the latest advancements in asthma therapeutics and to provide guidance for future investigations in this domain. Active, not recruiting --> Completed
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Biomarker, Clinical data, Journal: Biomarkers and clinical outcomes after tezepelumab cessation: extended follow-up from the 2-year DESTINATION study. (Pubmed Central) - Aug 24, 2024
P3
Active, not recruiting --> Completed This analysis reveals the benefits of continued tezepelumab treatment in the management of patients with severe, uncontrolled asthma, compared with stopping treatment after 2 years.
- |||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New trial, HEOR, Real-world evidence: ELBRUS: Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia (clinicaltrials.gov) - Aug 22, 2024
P=N/A, N=110, Not yet recruiting, Sponsor: AstraZeneca
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion date, Trial primary completion date: UPSTREAM-COPD: Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD (clinicaltrials.gov) - Aug 21, 2024
P2, N=80, Recruiting, Sponsor: Asger Sverrild
This analysis reveals the benefits of continued tezepelumab treatment in the management of patients with severe, uncontrolled asthma, compared with stopping treatment after 2 years. Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Dec 2025
- | Retrospective data, Journal: Comparative efficacy of biologics for patients with inadequately controlled asthma: A network meta-analysis. (Pubmed Central) - Aug 2, 2024
Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Dec 2025 Although there were no significant differences between the biologics in the overall study population, patients with eosinophil levels ?300
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, Combivent (ipratropium/salbutamol) / Boehringer Ingelheim, Fasenra (benralizumab) / AstraZeneca
A CASE OF INTRACTABLE WHEEZE IN A PATIENT WITH SEVERE ASTHMA DESPITE BIOLOGIC THERAPY (Convention Center Exhibit Hall: Rapid Fire Area 1A) - Jul 31, 2024 - Abstract #CHEST2024CHEST_4860;
At that time, he was also on tezepelumab having received twelve months of treatment...He reported having five exacerbations in the last year requiring prednisone...IgE was 19 and peripheral eosinophils were as high as 0.4 x10^9/L before starting benralizumab... This case highlights the importance of recognizing ECAC as a potential confounder for patients with severe, uncontrolled asthma not responding to conventional therapy.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
TEZEPELUMAB-EKKO IN ELDERLY ASTHMATICS: A CASE SERIES REVEALING REAL-WORLD INSIGHTS (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_4661;
This retrospective analysis of elderly patients receiving Tezepelumab-ekko revealed a remarkable reduction in asthma exacerbations, from 13 to 0, following treatment initiation. CLINICAL IMPLICATIONS: The significant improvement in mean ACT scores from 12.2 to 20.25 underscores the effectiveness of Tezepelumab-ekko in enhancing asthma control and quality of life in this challenging demographic.
- LONG-TERM SAFETY OF BIOLOGICS IN ASTHMA: A SYSTEMATIC LITERATURE REVIEW (Convention Center Exhibit Hall: Rapid Fire Area 3C) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3876;
The largest and longest safety evidence base was found for mepolizumab which showed the lowest treatment discontinuation rate due to AEs across comparable OLE/LTE studies with no notable increases in SAE rates, discontinuations, or mortality due to AE beyond 4.8 years of treatment. CLINICAL IMPLICATIONS: Long-term safety is a critical determinant of treatment choice for chronic conditions such as asthma.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA AND ALLERGIC RHINITIS GROUPED BY BASELINE BLOOD EOSINOPHIL COUNT: POOLED ANALYSIS OF PATHWAY AND NAVIGATOR (Convention Center Exhibit Hall: Rapid Fire Area 3A) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3440;
P2, P3
300 cells/?L. CLINICAL IMPLICATIONS: This analysis further demonstrates the efficacy of tezepelumab in patients with severe, uncontrolled asthma, including those with comorbid AR, irrespective of baseline BECs.
- EFFECTIVENESS OF BIOLOGICS IN ASTHMA: COMPARING REAL-WORLD EVIDENCE (Convention Center Exhibit Hall: Poster Area 2) - Jul 31, 2024 - Abstract #CHEST2024CHEST_3395;
However, these findings should be interpreted cautiously due to the retrospective nature of these included real-world studies. Treatment choices could have been influenced by underlying risk factors, temporal availability of biologics based on approval dates, and physician/patient preferences.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
EFFECT OF TEZEPELUMAB ON PATIENT-REPORTED ACTIVITY LEVELS AND SLEEP DISTURBANCE IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA: RESULTS FROM THE PHASE 3 NAVIGATOR STUDY (Convention Center Exhibit Hall: Rapid Fire Area 3B) - Jul 31, 2024 - Abstract #CHEST2024CHEST_2830;
P3
Tezepelumab treatment resulted in improvements compared with placebo in patient-reported activity levels and sleep disturbance items in patients with severe, uncontrolled asthma. CLINICAL IMPLICATIONS: These data further support the efficacy of tezepelumab in improving asthma symptoms and HRQoL in patients with severe, uncontrolled asthma.
- Xolair (omalizumab) / Roche, Novartis
SERUM SICKNESS-LIKE REACTION SECONDARY TO OMALIZUMAB (Convention Center Exhibit Hall: Poster Area 1) - Jul 31, 2024 - Abstract #CHEST2024CHEST_1083;
Serum-sickness like reactions are hypersensitivity reactions which can be seen with biologic therapies. Physicians should have a high index of suspicion when patients have arthralgias and constitutional symptoms temporally associated with exposure to these medications.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Successful Desensitization to Tezepelumab in a Polysorbate-Allergic Patient. (Pubmed Central) - Jul 29, 2024
Physicians should have a high index of suspicion when patients have arthralgias and constitutional symptoms temporally associated with exposure to these medications. No abstract available
- ||| Journal, Adverse events, Real-world evidence, Real-world: Real-World Safety Profile of Biologic Drugs for Severe Uncontrolled Asthma: A Descriptive Analysis from the Spanish Pharmacovigilance Database. (Pubmed Central) - Jul 27, 2024
Furthermore, the study highlights gaps between the reported ADRs and the information provided in SmPCs, signaling potential areas for improvement in drug safety monitoring and regulatory oversight. Finally, these findings may contribute to informed decision making in clinical practice and regulatory policy, ultimately advancing patient care and safety in the management of severe uncontrolled asthma.
- || Review, Journal: Immunogenicity of biologics used in the treatment of asthma. (Pubmed Central) - Jul 26, 2024
These can contribute to adverse events including infusion reactions, serum sickness, anaphylaxis and potentially disease activity due to loss of therapeutic function. Monitoring anti-drug antibodies (ADA) may allow prediction of future treatment-failure in some individuals allowing treatment cessation and switching therefore potentially limiting disease breakthrough.
- || Retrospective data, Review, Journal: Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jul 26, 2024
These results indicate the clinical benefit of omalizumab, dupilumab, and mepolizumab in patients with ABPA. Further randomized, controlled studies with a larger sample size and longer follow-up are needed to confirm these findings.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Comprehensive management of severe uncontrolled asthma: The case for TEZSPIRE - All faculty (C4) - Jul 21, 2024 - Abstract #ERS2024ERS_5976;
Further randomized, controlled studies with a larger sample size and longer follow-up are needed to confirm these findings. Sponsored by AstraZeneca.
- 289: Targeting TSLP: Addressing the multiple drivers of severe asthma (C4) - Jul 21, 2024 - Abstract #ERS2024ERS_5974;
Sponsored by AstraZeneca. Sponsored by AstraZeneca.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
ENRICHMENT OF TSLP GENE SIGNATURES IN OESOPHAGEAL TISSUE OF PATIENTS WITH ACTIVE EOSINOPHILIC OESOPHAGITIS: POTENTIAL FOR TREATMENT WITH TEZEPELUMAB (Science Lounge) - Jul 18, 2024 - Abstract #UEGW2024UEGW_1086;
P2, P3
These data suggest that blocking TSLP with tezepelumab may be a therapeutic option for EoE. The efficacy and safety of tezepelumab in patients with symptomatic and histologically active EoE are being assessed in the ongoing CROSSING study.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Late Breaking Abstract - Clinical efficacy of Tezepelumab in pre-selected non-Type 2 asthma patients (PS-10; Poster board no. 20) - Jul 16, 2024 - Abstract #ERS2024ERS_5846;
Conclusion This is the first case series demonstrating that patients with non-T2 asthma benefit from treatment with Tezepelumab regarding lung function, ACQ, and AQLQ. However, an extensive placebo-controlled trial is needed to confirm the clinically beneficial effects of Tezepelumab in non-T2 asthma patients.
- |||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New trial: T-ROSS: Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain (clinicaltrials.gov) - Jul 4, 2024
P=N/A, N=34, Recruiting, Sponsor: AstraZeneca
- || Clinical, Journal: Towards precision medicine in COPD: Targeting type 2 cytokines and alarmins. (Pubmed Central) - Jul 2, 2024
300 eosinophils/?L treated with dupilumab (anti-IL-4R?)...Several ongoing RCTs are evaluating the efficacy and safety of anti-TSLP (tezepelumab), anti-IL-33 (itepekimab, tozorakimab), and anti-ST2 (astegolimab) in patients with COPD, who experience exacerbations. In conclusion, targeting T2 inflammation or epithelial-derived alarmins might represent a step forward in precision medicine for the treatment of a subset of COPD.
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Tezepelumab improved chronic eosinophilic pneumonia in severe asthma patients with liver cirrhosis. (Pubmed Central) - Jun 26, 2024
Sinusitis also improved after ceasing OCS. This case suggested that tezepelumab may be useful as a treatment option for patients with CEP, especially those with liver dysfunction.
- |||||||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New P3 trial: ARRIVAL: Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. (clinicaltrials.gov) - Jun 25, 2024
P3, N=300, Not yet recruiting, Sponsor: AstraZeneca
- || Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Review, Journal, Stroma: Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy. (Pubmed Central) - Jun 19, 2024
Several clinical trials are evaluating the safety and efficacy of Tezepelumab in various inflammatory disorders. In this review, we will highlight major recent advances in understanding the functional role of TSLP, its involvement in Th2-related diseases, and its suitability as a target for biological therapies.
- |||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Trial completion date, Trial primary completion date: SUNRISE: Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (clinicaltrials.gov) - Jun 17, 2024
P3, N=207, Recruiting, Sponsor: AstraZeneca
In this review, we will highlight major recent advances in understanding the functional role of TSLP, its involvement in Th2-related diseases, and its suitability as a target for biological therapies. Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Apr 2025 --> Sep 2025
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Journal: Tezepelumab in a case of severe asthma exacerbation and influenza-pneumonia on VV-ECMO. (Pubmed Central) - Jun 17, 2024
After administration of a single dose Tezepelumab, a novel TLSP-inhibitor, and otherwise unchanged therapy we documented a significant reduction in intrinsic PEEP measured via a naso-gastric balloon catheter and a narrowing in the expiratory flow curve of the ventilator within 24 hours. The consecutive ventilatory improvement allowed the successful weaning from veno-venous ECMO therapy and invasive ventilation.
- || Review, Journal: Weighted Breaths: Exploring Biologic and Non-Biologic Therapies for Co-Existing Asthma and Obesity. (Pubmed Central) - Jun 15, 2024
Although many biologics presently indicated as add-on maintenance therapy for severe asthma exhibit efficacy in obese asthmatics, other phenotypes of asthma co-existing with obesity may be refractory to these medications. Thus, to improve quality of life and asthma control, it is imperative to identify therapeutic options for all existing phenotypes of obese asthma.
- | New trial: TARGET: Taiwan Severe Asthma Biologic Registry (clinicaltrials.gov) - Jun 12, 2024
P=N/A, N=500, Recruiting, Sponsor: Taichung Veterans General Hospital
- |||||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New trial: TPAP: Patient Characteristics, Treatment Patterns and Outcomes of Patients Enrolled in the Tezepelumab Patient Access Programme; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres (clinicaltrials.gov) - Jun 11, 2024
P=N/A, N=200, Recruiting, Sponsor: AstraZeneca
- | Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
New trial: Tezepelumab Treatment in Korean Severe Asthma Patients (clinicaltrials.gov) - Jun 3, 2024
P=N/A, N=100, Not yet recruiting, Sponsor: Asan Medical Center
- lunsekimig (SAR443765) / Sanofi
TSLP AND IL-13 Dual Blockade By Lunsekimig Provides Broader Benefits On Type-2 Inflammation (PS-14; Poster board no. 20) - May 31, 2024 - Abstract #ERS2024ERS_4807;
Indeed, lunsekimig was more potent in inhibiting TARC and eotaxin-3 production than targeting TSLP (tezepelumab) or IL-13 (lebrikizumab) alone in an allergen-stimulated triculture assay. Lunsekimig had significantly lowered plasma human IL
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab reduces the expression of MUC5AC in patients with asthma (A1) - May 31, 2024 - Abstract #ERS2024ERS_3516;
Anti-TSLP treatment reduces the expression of MUC5AC independent of T2-biomarker status, possibly through a downregulation of the EGFR pathway. This could mechanistically explain how tezepelumab reduces mucus plugging.
- GB-0895 / Generate Biomedicines
A long-acting high affinity anti-TSLP antibody (GB-0895) for severe asthma identified leveraging a proprietary machine learning platform (PS-10; Poster board no. 13) - May 31, 2024 - Abstract #ERS2024ERS_3005;
Conclusions GB-0895 has the potential for best-in-class dosing for patients with severe asthma. A phase 1 dose escalation trial in asthma patients is underway.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
ARRIVAL: a phase 3b study to assess potential for tezepelumab to reduce maintenance inhaled therapy and induce remission in patients with severe asthma (PS-9; Poster board no. 7) - May 31, 2024 - Abstract #ERS2024ERS_2979;
A phase 1 dose escalation trial in asthma patients is underway. ARRIVAL will assess the potential of tezepelumab to enable withdrawal of maintenance ICS while maintaining asthma control in patients with severe, uncontrolled asthma.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Can we trust the SOURCE ? Real world maintenance OCS reduction outcomes in complex severe asthmatics on Tezepelumab (PS-9; Poster board no. 6) - May 31, 2024 - Abstract #ERS2024ERS_2978;
ARRIVAL will assess the potential of tezepelumab to enable withdrawal of maintenance ICS while maintaining asthma control in patients with severe, uncontrolled asthma. Despite the findings of the SOURCE RCT, our study shows that in a real-world severe asthma cohort, 6 doses of Tezepelumab enabled 69% of patients to achieve ?50% mOCS dose reduction,with 46% being able to essentially taper off.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Pharmacokinetics, pharmacodynamics and safety of tezepelumab in children with asthma (PS-9; Poster board no. 5) - May 31, 2024 - Abstract #ERS2024ERS_2977;
P1
Despite the findings of the SOURCE RCT, our study shows that in a real-world severe asthma cohort, 6 doses of Tezepelumab enabled 69% of patients to achieve ?50% mOCS dose reduction,with 46% being able to essentially taper off. The PK, PD and safety after a single 70 mg dose of tezepelumab in children were as expected from previous studies in other age groups, supporting further development of tezepelumab for children with asthma.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Tezepelumab in eosinophilic granulomatosis with polyangiitis (EGPA) (PS-9; Poster board no. 4) - May 31, 2024 - Abstract #ERS2024ERS_2976;
Neither experienced an EGPA relapse. Conclusion In a first ever report of tezepelumab use in EGPA, we describe clinically important improvements in two patients with refractory EGPA.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
A comparison of T2 biomarker suppression with Tezepelumab in the real world and phase 3 NAVIGATOR study (PS-9; Poster board no. 3) - May 31, 2024 - Abstract #ERS2024ERS_2975;
In a RW severe asthma cohort, a large proportion of patients treated with tezepelumab continue to have evidence of T2 inflammation suggesting that other key drivers of IL-5 and IL-13 pathways remain active. The clinical significance requires further assessment.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Biomarkers and phenotyping: a holistic approach to asthma treatment with tezepelumab (PS-9; Poster board no. 2) - May 31, 2024 - Abstract #ERS2024ERS_2974;
P2, P3
The clinical significance requires further assessment. Changes in biomarker levels over 52 weeks were not associated with on-treatment AAER with tezepelumab treatment; however, changes in some biomarkers correlated with improvements in lung function, asthma symptoms and QoL.
- Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE) (Lehar 3) - May 31, 2024 - Abstract #ERS2024ERS_2677;
P2
Changes in biomarker levels over 52 weeks were not associated with on-treatment AAER with tezepelumab treatment; however, changes in some biomarkers correlated with improvements in lung function, asthma symptoms and QoL. Tezepelumab delayed the time to first moderate or severe COPD exacerbation, overall and across BEC subgroups.